GYRE Gyre Therapeutics, Inc.
Gyre Therapeutics, Inc. (GYRE) is expected to report earnings on November 5, 2026, after the market close. The consensus earnings estimate is a loss of $0.07 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +4.2% since its last earnings release on August 7, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Gyre Therapeutics, Inc.
Gyre Therapeutics Inc. is a biotechnology company. It focused on organ fibrosis and inflammatory diseases. The company's product pipeline primarily includes F573, F528 and F230. Gyre Therapeutics Inc., formerly known as Catalyst Biosciences Inc., is based in United States.
Sector
Healthcare
Industry
Biotechnology